{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T09:09:04Z","timestamp":1794733744849,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>It is unclear the role of longitudinal trajectory of serum uric acid (SUA) on the development of non-alcoholic fatty liver disease (NAFLD). We aimed to determine whether longitudinal SUA trajectories are associated with the risk of new-onset NAFLD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We explored the relationship between SUA trajectories and NAFLD in a cohort including 3822 participants. Individual\u2019s SUA trajectories from 2012 to 2014 were defined using group-based trajectory modeling analysis in four distinct patterns: trajectory 1 (n\u2009=\u2009991, 25.93%), trajectory 2 (n\u2009=\u20091421, 37.18%), trajectory 3 (n\u2009=\u20091156, 30.22%), and trajectory 4 (n\u2009=\u2009254, 6.67%). The logistic regression model was used to evaluate the association between SUA changing trajectories and subsequent NAFLD until 2016. Dose\u2013response relationship between SUA changing trajectories and NAFLD risk was evaluated through the testing of trajectory groups as a continuous variable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 2-year incidence of NAFLD was 13.27%. Compared with trajectory 1, the adjusted odds risk for NAFLD development was in a dose\u2013response relationship as follows: 1.27 (95% CI 0.91\u20131.78) for trajectory 2, 1.89 (95% CI 1.29\u20132.75) for trajectory 3, and 2.34 (95% CI 1.43\u20133.83) for trajectory 4. And this dose\u2013response relationship was not affected by age, sex, and abdominal obesity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Higher SUA changing trajectory is a risk factor for NAFLD. This finding highlights the importance of paying attention to SUA changing trajectory on the detection and prevention of NAFLD.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12967-020-02296-x","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T12:04:25Z","timestamp":1584619465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Zhimin","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaonan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,19]]},"reference":[{"key":"2296_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/apt.15163","volume":"49","author":"S Sookoian","year":"2019","unstructured":"Sookoian S, Pirola CJ. Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome\u2013translating knowledge from systems biology to the bedside. Aliment Pharmacol Ther. 2019;49:516\u201327.","journal-title":"Aliment Pharmacol Ther"},{"key":"2296_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2296_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"2296_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/jgh.12428","volume":"29","author":"Z Li","year":"2014","unstructured":"Li Z, Xue J, Chen P, Chen L, Yan S, Liu L. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol. 2014;29:42\u201351.","journal-title":"J Gastroenterol Hepatol"},{"key":"2296_CR5","first-page":"136","volume":"49","author":"G Darmawan","year":"2017","unstructured":"Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: a meta-analysis. Acta Med Indones. 2017;49:136\u201347.","journal-title":"Acta Med Indones"},{"key":"2296_CR6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.clinbiochem.2015.12.010","volume":"49","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Wei F, Fan Y. High serum uric acid and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Biochem. 2016;49:636\u201342.","journal-title":"Clin Biochem"},{"key":"2296_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jfma.2015.06.007","volume":"115","author":"M Agilli","year":"2016","unstructured":"Agilli M, Aydin FN. Association between serum uric acid and nonalcoholic fatty liver disease. J Formos Med Assoc. 2016;115:136.","journal-title":"J Formos Med Assoc"},{"key":"2296_CR8","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1111\/liv.13941","volume":"38","author":"C Xu","year":"2018","unstructured":"Xu C, Ma Z, Wang Y, Liu X, Tao L, Zheng D, et al. Visceral adiposity index as a predictor of NAFLD: a prospective study with 4-year follow-up. Liver Int. 2018;38:2294\u2013300.","journal-title":"Liver Int"},{"key":"2296_CR9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1186\/s12889-019-6887-x","volume":"19","author":"L Tao","year":"2019","unstructured":"Tao L, Li X, Zhang J, Liu J, Liu Y, Li H, et al. Association of commuting mode with dyslipidemia and its components after accounting for air pollution in the working population of Beijing, China. BMC Public Health. 2019;19:622.","journal-title":"BMC Public Health"},{"key":"2296_CR10","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.jhep.2015.01.019","volume":"62","author":"C Xu","year":"2015","unstructured":"Xu C, Wan X, Xu L, Weng H, Yan M, Miao M, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: one stone hits two birds. J Hepatol. 2015;62:1412\u20139.","journal-title":"J Hepatol"},{"key":"2296_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.2337\/dc09-1825","volume":"33","author":"MC Amato","year":"2010","unstructured":"Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diab Care. 2010;33:920\u20132.","journal-title":"Diab Care"},{"key":"2296_CR12","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1681\/ASN.2006040368","volume":"17","author":"YC Ma","year":"2006","unstructured":"Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937\u201344.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2296_CR13","first-page":"163","volume":"18","author":"F Jian-gao","year":"2010","unstructured":"Jian-gao F. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi. 2010;18(3):163\u20136.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"2296_CR14","first-page":"6905720","volume":"2018","author":"J Liu","year":"2018","unstructured":"Liu J, Tao L, Zhao Z, Mu Y, Zou D, Zhang J, et al. Two-year changes in hyperuricemia and risk of diabetes: a five-year prospective cohort study. J Diab Res. 2018;2018:6905720.","journal-title":"J Diab Res"},{"key":"2296_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2337\/dc18-S002","volume":"41","author":"American Diabetes, A","year":"2018","unstructured":"American Diabetes, A. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diab Care. 2018;41:13\u201327.","journal-title":"Diab Care"},{"key":"2296_CR16","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640\u20135.","journal-title":"Circulation"},{"key":"2296_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0049124101029003005","volume":"29","author":"BL Jones","year":"2001","unstructured":"Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2001;29:374\u201393.","journal-title":"Sociol Methods Res"},{"key":"2296_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.20982\/tqmp.05.1.p011","volume":"5","author":"H Andruff","year":"2009","unstructured":"Andruff H, Carraro N, Thompson A, Gaudreau P, Louvet B. Latent class growth modelling: a tutorial. Tutor Quant Methods Psychol. 2009;5:11\u201324.","journal-title":"Tutor Quant Methods Psychol"},{"issue":"1","key":"2296_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"Adams LA, Lymp JF, Sauver JS, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113\u201321.","journal-title":"Gastroenterology"},{"key":"2296_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2015.02.049","volume":"240","author":"T Zhang","year":"2015","unstructured":"Zhang T, Zhang C, Zhang Y, Tang F, Li H, Zhang Q, et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. Atherosclerosis. 2015;240:144\u20138.","journal-title":"Atherosclerosis"},{"key":"2296_CR21","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/liv.13478","volume":"37","author":"MA Niriella","year":"2017","unstructured":"Niriella MA, Pathmeswaran A, De Silva ST, Kasturiratna A, Perera R, Subasinghe CE, et al. Incidence and risk factors for non-alcoholic fatty liver disease: a 7-year follow-up study among urban, adult Sri Lankans. Liver Int. 2017;37:1715\u201322.","journal-title":"Liver Int"},{"key":"2296_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/liv.13299","volume":"37","author":"S Bellentani","year":"2017","unstructured":"Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37:81\u20134.","journal-title":"Liver Int"},{"key":"2296_CR23","first-page":"762820","volume":"2015","author":"R Liu","year":"2015","unstructured":"Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis. Biomed Res Int. 2015;2015:762820.","journal-title":"Biomed Res Int"},{"issue":"2","key":"2296_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2008.10.052","volume":"136","author":"CE Ruhl","year":"2009","unstructured":"Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and \u03b3-glutamyltransferase and mortality in the United States population. Gastroenterology. 2009;136(2):477\u2013485.e11.","journal-title":"Gastroenterology"},{"key":"2296_CR25","first-page":"3","volume":"2","author":"J Budd","year":"2020","unstructured":"Budd J, Cusi K. Non-alcoholic fatty liver disease: what does the primary care physician need to know? Am J Med. 2020;2:3\u20134.","journal-title":"Am J Med"},{"key":"2296_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2014.08.041","volume":"62","author":"VW Wong","year":"2015","unstructured":"Wong VW, Wong GL, Yeung DK, Lau TK, Chan CK, Chim AM, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2015;62:182\u20139.","journal-title":"J Hepatol"},{"key":"2296_CR27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12072-015-9682-5","volume":"10","author":"C Xu","year":"2016","unstructured":"Xu C. Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back. Hepatol Int. 2016;10:286\u201393.","journal-title":"Hepatol Int"},{"key":"2296_CR28","doi-asserted-by":"publisher","first-page":"14325","DOI":"10.1038\/srep14325","volume":"5","author":"Z Liu","year":"2015","unstructured":"Liu Z, Que S, Zhou L, Zheng S. Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: a meta-analysis of prospective studies. Sci Rep. 2015;5:14325.","journal-title":"Sci Rep"},{"key":"2296_CR29","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1210\/jc.2015-2527","volume":"100","author":"H Yuan","year":"2015","unstructured":"Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C, et al. Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies. J Clin Endocrinol Metab. 2015;100:4198\u2013207.","journal-title":"J Clin Endocrinol Metab"},{"key":"2296_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbrc.2014.04.080","volume":"447","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Hu Y, Huang T, Zhang Y, Li Z, Luo C, et al. High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochem Biophys Res Commun. 2014;447:707\u201314.","journal-title":"Biochem Biophys Res Commun"},{"key":"2296_CR31","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2337\/dc17-1318","volume":"41","author":"M Apostolopoulou","year":"2018","unstructured":"Apostolopoulou M, Gordillo R, Koliaki C, Gancheva S, Jelenik T, De Filippo E, et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis. Diab Care. 2018;41:1235\u201343.","journal-title":"Diab Care"},{"key":"2296_CR32","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/labinvest.2014.98","volume":"94","author":"YJ Choi","year":"2014","unstructured":"Choi YJ, Shin HS, Choi HS, Park JW, Jo I, Oh ES, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest. 2014;94:1114\u201325.","journal-title":"Lab Invest"},{"key":"2296_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.mce.2013.04.027","volume":"375","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Yamamoto T, Hisatome I, Li Y, Cheng W, Sun N, et al. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic beta cells. Mol Cell Endocrinol. 2013;375:89\u201396.","journal-title":"Mol Cell Endocrinol"},{"key":"2296_CR34","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","volume":"64","author":"X Wan","year":"2016","unstructured":"Wan X, Xu C, Lin Y, Lu C, Li D, Sang J, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64:925\u201332.","journal-title":"J Hepatol"},{"key":"2296_CR35","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/liv.13329","volume":"37","author":"K Wijarnpreecha","year":"2017","unstructured":"Wijarnpreecha K, Panjawatanan P, Lekuthai N, Thongprayoon C, Cheungpasitporn W, Ungprasert P. Hyperuricaemia and risk of nonalcoholic fatty liver disease: a meta-analysis. Liver Int. 2017;37:906\u201318.","journal-title":"Liver Int"},{"key":"2296_CR36","first-page":"305","volume":"19","author":"J Liang","year":"2015","unstructured":"Liang J, Pei Y, Gong Y, Liu XK, Dou LJ, Zou CY, et al. Serum uric acid and non-alcoholic fatty liver disease in non-hypertensive Chinese adults: the cardiometabolic risk in Chinese (CRC) study. Eur Rev Med Pharmacol Sci. 2015;19:305\u201311.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2296_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12944-017-0531-5","volume":"16","author":"X Zheng","year":"2017","unstructured":"Zheng X, Gong L, Luo R, Chen H, Peng B, Ren W, et al. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. Lipids Health Dis. 2017;16:202.","journal-title":"Lipids Health Dis"},{"key":"2296_CR38","doi-asserted-by":"publisher","first-page":"E104","DOI":"10.1111\/hepr.12734","volume":"47","author":"J Liu","year":"2017","unstructured":"Liu J, Xu C, Ying L, Zang S, Zhuang Z, Lv H, et al. Relationship of serum uric acid level with non-alcoholic fatty liver disease and its inflammation progression in non-obese adults. Hepatol Res. 2017;47:E104\u2013e112.","journal-title":"Hepatol Res"},{"key":"2296_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5009\/gnl14444","volume":"10","author":"HC Cho","year":"2016","unstructured":"Cho HC. Prevalence and factors associated with nonalcoholic fatty liver disease in a nonobese Korean population. Gut Liver. 2016;10:117\u201325.","journal-title":"Gut Liver"},{"issue":"3","key":"2296_CR40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00535-018-01542-w","volume":"54","author":"G Brar","year":"2019","unstructured":"Brar G, Tsukamoto H. Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science. J Gastroenterol. 2019;54(3):218\u201325.","journal-title":"J Gastroenterol"},{"key":"2296_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/flgastro-2013-100403","volume":"5","author":"JK Dyson","year":"2014","unstructured":"Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5:211\u20138.","journal-title":"Frontline Gastroenterol"},{"key":"2296_CR42","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s00125-016-3944-1","volume":"59","author":"H Yki-J\u00e4rvinen","year":"2016","unstructured":"Yki-J\u00e4rvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia. 2016;59:1104\u201311.","journal-title":"Diabetologia"},{"key":"2296_CR43","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1111\/liv.12842","volume":"35","author":"S Zelber-Sagi","year":"2015","unstructured":"Zelber-Sagi S, Ben-Assuli O, Rabinowich L, Goldstein A, Magid A, Shalev V, et al. The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort. Liver Int. 2015;35:2408\u201315.","journal-title":"Liver Int"},{"key":"2296_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000360229","volume":"65","author":"DS Nagin","year":"2014","unstructured":"Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab. 2014;65:205\u201310.","journal-title":"Ann Nutr Metab"},{"key":"2296_CR45","doi-asserted-by":"crossref","first-page":"e007607","DOI":"10.1161\/JAHA.117.007607","volume":"7","author":"Z Yuan","year":"2018","unstructured":"Yuan Z, Yang Y, Wang C, Liu J, Sun X, Liu Y, et al. Trajectories of long-term normal fasting plasma glucose and risk of coronary heart disease: a prospective cohort study. J Am Heart Assoc. 2018;7:e007607.","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02296-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-020-02296-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02296-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T05:45:25Z","timestamp":1666158325000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02296-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,19]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2296"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02296-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,19]]},"assertion":[{"value":"7 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were approved by Ethics Committee of Capital Medical University (NO: 2013SY26) and conformed to the guidelines of\u00a0Helsinki declaration and its later amendments or comparable ethical standards.\u00a0All data were collected after obtaining the informed consent form signed by all the participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}